| Therapeutic | Dostarlimab |
| Target | PDCD1/CD279/PD1 |
| Heavy Chain | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGTTVTVSS |
| Light Chain | DIQLTQSPSFLSAYVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTLHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQHYSSYPWTFGQGTKLEIK |
| 100% seqID Fv Structure | 7wsl [Fvs: HL] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 7wsl [Fvs: HL] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G4 |
| Highest Clinical Trial (Feb '25) | Approved |
| Estimated Status (Feb '25) | Active |
| Recorded Developmental Technology | |
| INN Year Proposed | 2018 |
| INN Year Recommended | 2019 |
| Companies Involved | AnaptysBio, European Network of Gynaecological Oncological Trial Groups, GlaxoSmithKline, TESARO |
| Conditions Approved | Endometrial cancer, Solid tumours |
| Conditions Active | Fallopian tube cancer, Ovarian cancer, Peritoneal cancer, Non-small cell lung cancer, Breast cancer, Cervical cancer, Liver cancer, Malignant melanoma, Neuroendocrine tumours, Pancreatic cancer, Rectal cancer, Small cell lung cancer, Squamous cell cancer |
| Conditions Discontinued | na |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
